z-logo
open-access-imgOpen Access
Placental protein 13
Author(s) -
Ranjeeta Gadde,
CD Dayanand,
SR Sheela
Publication year - 2018
Publication title -
journal of circulating biomarkers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 11
ISSN - 1849-4544
DOI - 10.1177/1849454418786159
Subject(s) - syncytiotrophoblast , hemopexin , placentation , biology , glycan , preeclampsia , receptor , placenta , glycoprotein , microbiology and biotechnology , biochemistry , fetus , pregnancy , heme , genetics , enzyme
Placental protein 13 (PP13), a glycan binding protein predominantly expressed in syncytiotrophoblast, dimeric in nature, lacks N-terminal signal peptide, bypasses the endoplasmic reticulum, and secretes into maternal circulation as exosomes or microvesicles. PP13 has jelly roll fold conformation with conserved carbohydrate recognition domain which specifically binds to β-galactosides of the glycan receptors during placentation. PP13 binds to glycosylated receptors on human erythrocytes and brings about hemagglutination by the property of lectin activity; other functions are immunoregulation and vasodilation during placentation and vascularization. The gene LGALS13 located on 19q13.2 comprising four exons expresses a 32-kDa protein with 139 amino acid residues, PP13. Impaired expression due to mutation in the gene leads to a nonfunctional truncated PP13. The low serum levels predict high risk for the onset of preeclampsia or obstetric complications. Hence, PP13 turned to be an early marker for risk assessment of preeclampsia. The recombinant PP13 and monoclonal antibodies availability help for replenishing PP13 in conditions with low serum levels and for detection and prevention of preeclampsia, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom